Erasca (ERAS) Cash from Financing Activities (2020 - 2026)
Erasca (ERAS) reported Cash from Financing Activities of $244.7 million for Q1 2026, up 741306.06% on a YoY basis from N/an in Q1 2025, and up 42450.26% quarter-over-quarter from $575000.0 in Q4 2025.
Erasca (ERAS) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Erasca has reported Cash from Financing Activities for 7 years, with the latest figure at $244.7 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities rose 741306.06% year-over-year to $244.7 million; the trailing twelve-month figure through Mar 2026 stood at $245.7 million (up 5.1% YoY), and the FY2025 full-year result was $1.1 million, down 99.54% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $244.7 million, up from $575000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $244.7 million in Q1 2026, with the low at $7000.0 in Q3 2023.
- Historically, Cash from Financing Activities has averaged $34.5 million across 5 years, with a median of $575000.0 in 2025.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities slumped 99.87% — and 2026, when it surged 741306.06%.
- Erasca's Cash from Financing Activities stood at $96.2 million in 2022, then plunged by 99.53% to $456000.0 in 2023, then jumped by 75.66% to $801000.0 in 2024, then retreated by 28.21% to $575000.0 in 2025, then jumped by 42450.26% to $244.7 million in 2026.
- The last three Cash from Financing Activities figures came in at $244.7 million (Q1 2026), $575000.0 (Q4 2025), and $41000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Erasca | 4.16 Bn | 3.92 Bn | - | 244.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 244.66 Mn |
| Mar 31, 2026 | 244.66 Mn |
| Dec 31, 2025 | 575,000.00 |
| Dec 31, 2025 | 575,000.00 |
| Sep 30, 2025 | 41,000.00 |
| Sep 30, 2025 | 41,000.00 |
| Jun 30, 2025 | 447,000.00 |
| Jun 30, 2025 | 447,000.00 |
| Mar 31, 2025 | 33,000.00 |
| Mar 31, 2025 | 33,000.00 |
| Dec 31, 2024 | 801,000.00 |
| Dec 31, 2024 | 801,000.00 |
| Sep 30, 2024 | 21.10 Mn |
| Sep 30, 2024 | 21.10 Mn |
| Jun 30, 2024 | 211.87 Mn |
| Jun 30, 2024 | 211.87 Mn |
| Mar 31, 2024 | 6.93 Mn |
| Mar 31, 2024 | 6.93 Mn |
| Dec 31, 2023 | 456,000.00 |
| Dec 31, 2023 | 456,000.00 |